1157. The Clinical Impact of Casirivimab–Imdevimab Monoclonal Antibody Therapy (CIMAT) in COVID-19 patients: A real-world insight from India.

BACKGROUND: Various clinical studies from developed countries support the use of Casirivimab–Imdevimab Monoclonal Antibody Therapy (CIMAT) to treat outpatients with mild to moderate coronavirus disease-19 (COVID-19). However, the real-world clinical data from India, owing to the portrayed benefits,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kochuparambil, Jose J, Issac, Aleena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752330/
http://dx.doi.org/10.1093/ofid/ofac492.995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752330/
http://dx.doi.org/10.1093/ofid/ofac492.995

Ejemplares similares